TMCnet News

Rotavirus Infections Therapeutics Market - Pipeline Review, H2 2017 - Research and Markets
[December 18, 2017]

Rotavirus Infections Therapeutics Market - Pipeline Review, H2 2017 - Research and Markets


The "Rotavirus Infections - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.

Rotavirus Infections - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stagesare 2, 1, 1, 5 and 2 respectively. Similarly, the Universities portfolio in Phase II and Discovery stages comprises 4 and 1 molecules, respectively.



Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key Topics Covered:


  1. Introduction
  2. Rotavirus Infections - Overview
  3. Rotavirus Infections - Therapeutics Development
  4. Pipeline Overview
  5. Pipeline by Companies
  6. Pipeline by Universities/Institutes
  7. Products under Development by Companies
  8. Products under Development by Universities/Institutes
  9. Rotavirus Infections - Therapeutics Assessment
  10. Assessment by Target (News - Alert)
  11. Assessment by Mechanism of Action
  12. Assessment by Route of Administration
  13. Assessment by Molecule Type
  14. Rotavirus Infections - Companies Involved in Therapeutics Development
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech International Ltd
  • Biological E Ltd
  • Curevac AG
  • Medicago Inc
  • Nanotherapeutics Inc
  • Serum Institute of India Ltd
  • UMN Pharma Inc
  • Wuhan Institute of Biological Products Co Ltd

For more information about this report visit https://www.researchandmarkets.com/research/fzh5bs/rotavirus?w=4


[ Back To TMCnet.com's Homepage ]